Joel Dutschler

Sankt Gallen, SG, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Anti-Integrin αvβ6 Autoantibodies Distinguish Ulcerative Colitis From Crohn's Disease With High Diagnostic Accuracy and Outperform ANCA and ASCA Status: A Prospective Cross-Sectional Study.

Anti-Integrin αvβ6 Autoantibodies Distinguish Ulcerative Colitis From Crohn's Disease With High Diagnostic Accuracy and Outperform ANCA and ASCA Status: A Prospective Cross-Sectional Study.

Journal: Alimentary pharmacology & therapeutics

Published: June 12, 2026

XBB.1.5 COVID-19 mRNA Vaccines Induce Inadequate Mucosal Immunity in Patients with Inflammatory Bowel Disease.

XBB.1.5 COVID-19 mRNA Vaccines Induce Inadequate Mucosal Immunity in Patients with Inflammatory Bowel Disease.

Journal: Vaccines

Published: May 24, 2025

STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.

STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease.

Journal: Vaccines

Published: October 02, 2024

XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.

XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.

Journal: Alimentary pharmacology & therapeutics

Published: August 28, 2024

Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease.

Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease.

Journal: Vaccines

Published: June 07, 2024

STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.

STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.

Journal: Alimentary pharmacology & therapeutics

Published: July 03, 2023

Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.

Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.

Journal: Alimentary pharmacology & therapeutics

Published: August 23, 2022

Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgery.

Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgery.

Journal: PloS one

Published: February 20, 2020

Effect of elevated serum alcohol level on the outcome of severely injured patients.

Effect of elevated serum alcohol level on the outcome of severely injured patients.

Journal: Emergency medicine journal : EMJ

Published: July 16, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026